Study of S1 Efficacy and Toxicity as Second-line Treatment on Inoperable or Advanced Gastric Cancers
Recruitment status was: Recruiting
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Study of S1 Efficacy and Toxicity as Second-line Treatment on Inoperable or Advanced Gastric Cancers|
|Study Start Date:||February 2012|
|Estimated Study Completion Date:||October 2012|
TS, DPD and OPRT are the key enzymes on the metabolic pathway of 5-Fu. We will retrospectively analyze the clinicopathological features of the patients who have suffered an inoperative or recurrent gastric cancers and administrated with S-1, such as the overall survival (OS), progressive-free survival (PFS), Lauren's classification and toxicity of S1, etc. We will divide the patients into several subgroups according to the parameters above, and then investigate the correlation between the parameters and the expression of TS, DPD and OPRT.
All of the analysis is retrospective, there is no different treatment operation once the subject enrolled in this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01650766
|307 Hospital of PLA|
|Beijing, Beijing, China, 100071|
|Principal Investigator:||Xu Jianming, M.D.||The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|